The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms
Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, outlines the results of a Phase II study evaluating the safety and efficacy of tislelizumab in patients with relapsed/refractory (R/R) NK/T-cell lymphoma, peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) (NCT03493451). The trial reported a promising overall response rate (ORR) in patients with CTCL but not in patients with PTCL and NK/T-cell lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
